stockportfolio.pro
ILMN vs INCY: Which Stock Is the Better Buy?
Illumina, Inc. and Incyte Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ILMN vs INCY, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Illumina, Inc. (ILMN) | Incyte Corporation (INCY) | |
|---|---|---|
| Market cap | $24.7B | $23.3B |
| Revenue (latest FY) | $4.34B | $5.14B |
| Net income (latest FY) | $850.00M | $1.29B |
| Revenue growth (5y CAGR) | 6.0% | 14.0% |
| Net margin | 19.6% | 25.0% |
| Return on equity | 31.2% | 24.9% |
| P/E ratio | 29.6 | 16.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 8 |
| Positive free cash flow | Yes | — |
See the full ILMN vs INCY breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ILMN's full financials → Open INCY's full financials →More comparisons
Frequently asked questions
Which is bigger, ILMN or INCY?
Illumina, Inc. is larger by market capitalization — $24.7B versus $23.3B.
Which grows faster, ILMN or INCY?
Over the last five fiscal years, Incyte Corporation grew revenue faster — 14.0%/yr versus 6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.